1. In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo.
In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. Athymic nude mice inoculated s.c. with RMG2 cells were assigned into two treatment groups; bevacizumab (n = 5) or placebo (n = 5). B, the effect of perifosine on CCC that had acquired resistance to bevacizumab. Athymic nude mice that were inoculated s.c. with RMG2 cells and received bevacizumab treatment for 3 weeks. Then, the mice were assigned into two treatment groups; bevaizumab (n = 5) or perifosine (n = 5). Tumor volumes were monitored weekly, and growth curves of each treatment groups are shown. Points, mean; bars, SD (*, P < 0.05).
Tomoyuki Sasano et al. Mol Cancer Res 2015;13:
©2015 by American Association for Cancer Research